Will A/C Diagnostics break from Axis to sell its own test?
This article was originally published in Clinica
The Axis-Shield deal was a very public coming together of two small companies. Both of them had competing technologies for homocysteine measurement. Their alternative to merger was five years of patent litigation. However, there was another deal with a homocysteine assay company struck around the same time, which attracted little publicity from Axis.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.